Cubist reaches milestone
Cubist has reached a second milestone in its three year collaboration with Novartis, which is using Cubists' proprietary VITA technology (validation in vivo of targets and assays for antiinfectives). Cubist will receive a milestone payment for the delivery of this validated target and high throughput screening assay for antiinfective drug discovery.